Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease

R Kiesslich, C A Duckworth, D Moussata, A Gloeckner, L G Lim, M Goetz, D M Pritchard, P R Galle, M F Neurath, A J M Watson, R Kiesslich, C A Duckworth, D Moussata, A Gloeckner, L G Lim, M Goetz, D M Pritchard, P R Galle, M F Neurath, A J M Watson

Abstract

Objectives: Loss of intestinal barrier function plays an important role in the pathogenesis of inflammatory bowel disease (IBD). Shedding of intestinal epithelial cells is a potential cause of barrier loss during inflammation. The objectives of the study were (1) to determine whether cell shedding and barrier loss in humans can be detected by confocal endomicroscopy and (2) whether these parameters predict relapse of IBD.

Methods: Confocal endomicroscopy was performed in IBD and control patients using intravenous fluorescein to determine the relationship between cell shedding and local barrier dysfunction. A grading system based on appearances at confocal endomicroscopy in humans was devised and used to predict relapse in a prospective pilot study of 47 patients with ulcerative colitis and 11 patients with Crohn's disease.

Results: Confocal endomicroscopy in humans detected shedding epithelial cells and local barrier defects as plumes of fluorescein effluxing through the epithelium. Mouse experiments demonstrated inward flow through some leakage-associated shedding events, which was increased when luminal osmolarity was decreased. In IBD patients in clinical remission, increased cell shedding with fluorescein leakage was associated with subsequent relapse within 12 months after endomicroscopic examination (p<0.001). The sensitivity, specificity and accuracy for the grading system to predict a flare were 62.5% (95% CI 40.8% to 80.4%), 91.2% (95% CI 75.2 to 97.7) and 79% (95% CI 57.7 to 95.5), respectively.

Conclusions: Cell shedding and barrier loss detected by confocal endomicroscopy predicts relapse of IBD and has potential as a diagnostic tool for the management of the disease.

Conflict of interest statement

Competing interests: RK has an unrestricted grant from Pentax Europe and has received instruments for free via Optiscan. All other authors have no competing interests.

Figures

Figure 1
Figure 1
Confocal endomicroscopic imaging of epithelial cell shedding in the terminal ileum. (A) Fluorescein images capillaries beneath epithelial cells (block arrow) and the lateral intracellular space between epithelial cells (line arrow). (B) Epithelial cells become permeable to fluorescein prior to shedding (line arrow). (C–E) Fluorescein fluorescence signal is intense as shedding cells move out of the epithelial monolayer. (F) Intensely fluorescent shedding epithelial cells seen en face.
Figure 2
Figure 2
Loss of barrier function visualised by confocal endomicroscopy. (A) Intact barrier function with no escape of fluorescein into the gut lumen (arrow). (B) Fluorescein in the gap in the epithelium left by a shedding cell (arrow). Cellular debris from the shedding cell can be seen in the lumen. (C) efflux of fluorescein out of blood vessels (block arrow) into the lateral intercellular space. Efflux into the lumen is constrained at the apical border (block arrows). A plume of fluorescein effluxing through the gap left behind a shedding cell (line arrow). (D) Multiple sites of efflux of fluorescein through the epithelium into gut lumen (arrows). Note the increased fluorescence in the gut lumen. (E) Microerosion (arrow) where more than one epithelial cell has been lost at one site exposing a capillary to the lumen. Note the functional relevance of this lesion as there is efflux of fluorescein into the lumen.
Figure 3
Figure 3
(A) Localised fluorescein leak is preceded by cell shedding. Intravenous Alexa-dextran 647 (MW 10 000) shown in red and Hoechst 33342 labelled nuclei in blue. Images at 0, 5, 15 and 28 min relative to the start of cell shedding. (B–E) Dextran movement across small intestinal epithelia. Luminal FITC-dextran (MW 4000) shown in green. Intravenous Alexa-dextran 647 (MW 10 000) shown in red and combined images shown with Hoechst 33342 labelled nuclei. Dextran leakage from circulation into lumen in an outward direction (B–D), from lumen in an inward direction (E–G), in both inward and outward directions (H–J) and no movement of inward or outward dextran (K–M).
Figure 4
Figure 4
Analysis of loss of local barrier function and prediction of relapse of inflammatory bowel disease (IBD). Dextran movement (Luminal FITC-dextran (MW 4000) and intravenous Alexa-dextran 647 (MW 10 000)) through small intestinal epithelium at the site of epithelial cell shedding from luminal perfusion solutions of either 300 mOsm/l (black) and 246 mOsm/l (grey) solutions. (A) Percentage of events that show no dextran movement (sealed) and dextran leakage (leakage) in either the inward or the outward directions. (B) Percentage movement of dextran in an inward, outward or inward and outward direction from the leakage group. *p

References

    1. Duerksen DR, Wilhelm-Boyles C, Parry DM. Intestinal permeability in long-term follow-up of patients with celiac disease on a gluten-free diet. Dig Dis Sci 2005;50:785–90
    1. Berkes J, Viswanathan VK, Savkovic SD, et al. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut 2003;52:439–51
    1. Meddings J. The significance of the gut barrier in disease. Gut 2008;57:438–40
    1. Marchiando AM, Graham WV, Turner JR. Epithelial barriers in homeostasis and disease. Annu Rev Pathol 2010;5:119–44
    1. Peeters M, Ghoos Y, Maes B, et al. Increased permeability of macroscopically normal small bowel in Crohn's disease. Dig Dis Sci 1994;39:2170–6
    1. Peeters M, Geypens B, Claus D, et al. Clustering of increased small intestinal permeability in families with Crohn's disease. Gastroenterology 1997;113:802–7
    1. May GR, Sutherland LR, Meddings JB. Is small intestinal permeability really increased in relatives of patients with Crohn's disease? Gastroenterology 1993;104:1627–32
    1. Wyatt J, Vogelsang H, Hubl W, et al. Intestinal permeability and the prediction of relapse in Crohn's disease. Lancet 1993;341:1437–9
    1. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007;56:61–72
    1. Marchiando AM, Shen L, Graham WV, et al. Caveolin-1-dependent occludin endocytosis is required for TNF-induced tight junction regulation in vivo. J Cell Biol 2010;189:111–26
    1. Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology 2009;136:551–63
    1. Arrieta MC, Madsen K, Doyle J, et al. Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2009;58:41–8
    1. Guan Y, Watson AJ, Marchiando AM, et al. Redistribution of the tight junction protein ZO-1 during physiologic shedding of mouse intestinal epithelial cells. Am J Physiol Cell Physiol 2011;300:C1404–14
    1. Kiesslich R, Goetz M, Angus EM, et al. Identification of epithelial gaps in human small and large intestine by confocal endomicroscopy. Gastroenterology 2007;133:1769–78
    1. Watson AJ, Duckworth CA, Guan Y, et al. Mechanisms of epithelial cell shedding in the Mammalian intestine and maintenance of barrier function. Ann N Y Acad Sci 2009;1165:135–42
    1. Marchiando AM, Shen L, Graham VW, et al. The epithelial barrier is maintained by in vivo tight junction expansion during pathologic intestinal epithelial shedding. Gastroenterology 2011;140:1208–18
    1. Liu JJ, Wong K, Thiesen AL, et al. Increased epithelial gaps in the small intestines of patients with inflammatory bowel disease: density matters. Gastrointest Endosc 2011;73:1174–80
    1. Arrieta MC, Bistritz L, Meddings JB. Alterations in intestinal permeability. Gut 2006;55:1512–20
    1. Meddings JB, Sutherland LR, Byles NI, et al. Sucrose: a novel permeability marker for gastroduodenal disease. Gastroenterology 1993;104:1619–26
    1. Hilsden RJ, Meddings JB, Sutherland LR. Intestinal permeability changes in response to acetylsalicylic acid in relatives of patients with Crohn's disease. Gastroenterology 1996;110:1395–403
    1. Munkholm P, Langholz E, Hollander D, et al. Intestinal permeability in patients with Crohn's disease and ulcerative colitis and their first degree relatives. Gut 1994;35:68–72
    1. Schulzke JD, Fromm M, Bentzel CJ, et al. Adaptation of the jejunal mucosa in the experimental blind loop syndrome: changes in paracellular conductance and tight junction structure. Gut 1987;28:159–64
    1. Kroesen AJ, Dullat S, Schulzke JD, et al. Permanently increased mucosal permeability in patients with backwash ileitis after ileoanal pouch for ulcerative colitis. Scand J Gastroenterol 2008;43:704–11
    1. Fromm M, Krug SM, Zeissig S, et al. High-resolution analysis of barrier function. Ann N Y Acad Sci 2009;1165:74–81
    1. Gitter AH, Wullstein F, Fromm M, et al. Epithelial barrier defects in ulcerative colitis: characterization and quantification by electrophysiological imaging. Gastroenterology 2001;121:1320–8
    1. Watson AJ, Chu S, Sieck L, et al. Epithelial barrier function in vivo is sustained despite gaps in epithelial layers. Gastroenterology 2005;129:902–12
    1. Gunzel D, Florian P, Richter JF, et al. Restitution of single-cell defects in the mouse colon epithelium differs from that of cultured cells. Am J Physiol Regul Integr Comp Physiol 2006;290:R1496–507
    1. Vermeire S, Schreiber S, Sandborn WJ, et al. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010;8:357–63
    1. Hirai F, Matsui T, Aoyagi K, et al. Validity of activity indices in ulcerative colitis: comparison of clinical and endoscopic indices. Dig Endosc 2010;22:39–44
    1. Shen L, Weber CR, Raleigh DR, et al. Tight junction pore and leak pathways: a dynamic duo. Annu Rev Physiol 2011;73:283–309
    1. Bullen TF, Forrest S, Campbell F, et al. Characterization of epithelial cell shedding from human small intestine. Lab Invest 2006;86:1052–63
    1. Gitter AH, Bertog M, Schulzke J, et al. Measurement of paracellular epithelial conductivity by conductance scanning. Pflugers Arch 1997;434:830–40
    1. Epple HJ, Schneider T, Troeger H, et al. Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients. Gut 2009;58:220–7
    1. Salim SY, Soderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:362–81
    1. Fritz T, Niederreiter L, Adolph T, et al. Crohn's disease: NOD2, autophagy and ER stress converge. Gut 2011;60:1580–8
    1. Lee JS. Contraction of villi and fluid transport in dog jejunal mucosa in vitro. Am J Physiol 1971;221:488–95
    1. Lee JS. Epithelial cell extrusion during fluid transport in canine small intestine. Am J Physiol 1977;232:E408–14
    1. Moore R, Carlson S, Madara JL. Villus contraction aids repair of intestinal epithelium after injury. Am J Physiol 1989;257:G274–83
    1. Ahmed T, Rieder F, Fiocchi C, et al. Pathogenesis of postoperative recurrence in Crohn's disease. Gut 2011;60:553–62
    1. Su L, Nalle SC, Sullivan EA, et al. Genetic ablation of myosin light chain kinase limits epithelial barrier dysfunction and attenuates experimental inflammatory bowel disease. Gastroenterology 2009;136:abstract.

Source: PubMed

3
Subscribe